MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Neurocrine Biosciences Inc

Abrir

SetorSaúde

136.03 -0.68

Visão Geral

Variação de preço das ações

24h

Atual

Mín

136.02

Máximo

137.75

Indicadores-chave

By Trading Economics

Rendimento

100M

108M

Vendas

115M

688M

P/E

Médio do Setor

41.997

35.739

Margem de lucro

15.636

Funcionários

1,800

EBITDA

129M

153M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+22.86% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

679M

14B

Abertura anterior

136.71

Fecho anterior

136.03

Sentimento de Notícias

By Acuity

21%

79%

44 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Neurocrine Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de jan. de 2025, 00:03 UTC

Ações em Alta

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Neurocrine Biosciences Inc Previsão

Preço-alvo

By TipRanks

22.86% parte superior

Previsão para 12 meses

Média 168 USD  22.86%

Máximo 200 USD

Mínimo 124 USD

Com base em 26 analistas de Wall Street que oferecem metas de preço de 12 meses para Neurocrine Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

26 ratings

23

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

109.55 / 121.61Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

44 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
help-icon Live chat